Safety assessment of DPI-4452, a cyclic peptide targeting Carbonic Anhydrase IX

Poster presented at ACT 43rd Annual Meeting

Inês Borrego1, Frédéric Massière1, Antoine Attinger1, Anne Schumann 2, Aileen Hoehne 2, Frank Osterkamp 2, Ulf Andersson1

1Debiopharm, Lausanne, SWITZERLAND
2 3B Pharmaceuticals GmbH, Berlin, GERMANY


The transmembrane metalloprotease Carbonic Anhydrase IX (CAIX) represents an attractive diagnostic and therapeutic target in hypoxic solid tumors such as Colorectal Cancer (CRC) and clear cell Renal Cell Carcinoma (ccRCC), with limited expression in healthy organs.

DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage that can be labelled with different radionuclides for theranostic purposes.